TAVR for intermediate-risk patients: the PARTNER 2 trial

TAVR for intermediate-risk patients: the PARTNER 2 trial [1]

The PARTNER 2A trial randomized 2032 patients at intermediate operative risk (mean STS score of 6) to undergo either transcatheter or surgical aortic valve replacement. The primary endpoint of all-cause death or disabling stroke at 2 years was comparable for the two treatments: TAVR 19.3% versus SAVR 21.1%. A subgroup analysis of patients eligible for transfemoral aortic valve replacement even suggested superior outcomes for TAVR as compared to surgery (HR 0.79, 95% CI 0.62-1.00, P=0.05).

Source name:

N Engl J Med

Resource link:

http://www.nejm.org/doi/full/10.1056/NEJMoa1514616 [3]

Taxonomy:

Valve Disease [4]

TAVR (TAVI) [5]

Subspecialty(ies):

Cardiac [6]

Author(s):

Martin B. Leon, Craig R. Smith, Michael J. Mack, Raj R. Makkar, Lars G. Svensson, Susheel K. Kodali, Vinod H. Thourani, E. Murat Tuzcu, D. Craig Miller, Howard C. Herrmann, Darshan Doshi, David J. Cohen, Augusto D. Pichard, Samir Kapadia, Todd Dewey, Vasilis Babaliaros, Wilson Y. Szeto, Mathew R. Williams, Dean Kereiakes, Alan Zajarias, Kevin L. Greason, Brian K. Whisenant, Robert W. Hodson, Jeffrey W. Moses, Alfredo Trento, David L. Brown, William F. Fearon, Philippe Pibarot, Rebecca T. Hahn, Wael A. Jaber, William N. Anderson, Maria C. Alu, and John G. Webb, for the PARTNER 2 Investigators

Taxonomy2018 vocabulary term reference:

Transcatheter [7]

Aortic valve disease [8]